There are currently 590 clinical trials in Omaha, Nebraska looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Nebraska Medical Center, Creighton University Medical Center, Nebraska Methodist Hospital and Alegent Health Bergan Mercy Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
GEMINI-NSCLC: NSCLC Biomarker Study
Recruiting
GEMINI NSCLC Study is a non-interventional study that will be collecting clinical and molecular health information from patients with NSCLC who will receive longitudinal blood collection in addition to their standard of care therapy and disease surveillance with the goals of identifying the molecular evolution of lung cancer with standard of care therapy, and determining the utility of ctDNA dynamics to predict risk of recurrence and therapeutic outcomes.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Nebraska Cancer Specialists, Omaha, Nebraska
Conditions: Non-Small Cell Lung Cancer
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: Skin Specialists PC, Omaha, Nebraska
Conditions: Prurigo Nodularis
A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer
Recruiting
The primary purpose of this study is to evaluate the safety, tolerability, and efficacy of SYNC-T Therapy SV-102 and to identify the maximum tolerated dose (MTD) and/or selected dose for phase 2b study.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/28/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Metastatic Castration-resistant Prostate Cancer
Registry of Avance® Nerve Graft's Utilization and Recovery Outcomes Post Peripheral Nerve Reconstruction
Recruiting
This study is a registry of general use of Avance Nerve Graft and is intended to evaluate the uses, response rates, and safety of Avance Nerve Graft in the real-life clinical setting. Optional addendums 1 and 2 included in the protocol are intended to establish comparative groups and focused subgroups within the registry.
Gender:
ALL
Ages:
All
Trial Updated:
07/25/2025
Locations: Sensation-NOW: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Peripheral Nerve Injuries
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
Recruiting
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2025
Locations: Research Site, Omaha, Nebraska
Conditions: Non-Small Cell Lung Cancer
Product Surveillance Registry
Recruiting
The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.
Gender:
ALL
Ages:
All
Trial Updated:
07/24/2025
Locations: Not set, Omaha, Nebraska
Conditions: Cardiac Rhythm Disorders, Urological Disorders, Neurological Disorders, Cardiovascular Disorders, Digestive Disorders, Intracranial Aneurysm, Mechanical Circulatory Support, Respiratory Therapy, Aortic, Peripheral Vascular and Venous Disorders, Minimally Invasive Surgical Procedures, Diagnostic Techniques and Procedures, Surgical Procedures, Operative, Renal Insufficiency, Neurovascular, Coronary Artery Disease, Ear, Nose and Throat Disorder
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: Creighton University Clinical Research Office ( Site 0123), Omaha, Nebraska
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer
Recruiting
This is an open label, phase I, multi-center study aiming to assess the safety and tolerability in patients with metastatic castration resistant prostate cancer (mCRPC).
Gender:
MALE
Ages:
18 years and above
Trial Updated:
07/24/2025
Locations: Xcancer (Urology Cancer Center), Omaha, Nebraska
Conditions: Prostate Cancer (Adenocarcinoma), MCRPC (metastatic Castration-resistant Prostate Cancer)
Pancreatic Cancer Early Detection Consortium
Recruiting
The purpose of the Pancreatic Cancer Early Detection (PRECEDE) Consortium is to conduct research on multiple aspects of early detection and prevention of pancreatic ductal adenocarcinoma (PDAC) by establishing a multisite cohort of individuals with family history of PDAC and/or individuals carrying pathogenic/likely pathogenic germline variants (PGVs) in genes linked to PDAC risk for longitudinal follow up.
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
07/23/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Pancreas Cancer, Pancreas Cyst, Pancreatic Ductal Adenocarcinoma, Genetic Predisposition
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
07/23/2025
Locations: Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha, Nebraska
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1
Recruiting
The goal of this clinical trial is to: 1) evaluate the safety and recommended dose of the drug OT-101/Trabedersen when combined with Pembrolizumab and 2) determine the efficacy of the combination therapy in adults with certain types of Non-Small Cell Lung Cancer. The main question(s) it aims to answer are: * What medical problems to participants have when taking OT101 together with Pembrolizumab? * What is the correct dose of OT-101 to use when evaluating the safety and efficacy of the combinat... Read More
Gender:
ALL
Ages:
19 years and above
Trial Updated:
07/23/2025
Locations: University of Nebraska Medical Center, Omaha, Nebraska
Conditions: Non-small Cell Lung Cancer
Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301)
Recruiting
This study will assess the serum uric acid lowering effect and safety of AR882 in gout patients at two doses compared to placebo over 12 months
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/23/2025
Locations: Arthrosi Investigative Site (684), Omaha, Nebraska +1 locations
Conditions: Gout, Arthritis, Gouty, Hyperuricemia, Gout Chronic